Geneva, 17 February 2026

Essential Pharma, a global specialty pharmaceutical company focused on delivering medicines to small, underserved or rare disease populations, has announced the acquisition of Ventavis® (iloprost trometamol) from Bayer AG, including rights to the accompanying Breelib® nebuliser delivery technology.

Ventavis® is an established inhaled prostacyclin analogue indicated for the treatment of adult patients with primary pulmonary hypertension (NYHA functional class III), a rare condition characterised by elevated blood pressure in the pulmonary arteries. The product is commercially available in more than 60 markets globally. Under the terms of the transaction, Essential Pharma has acquired rights to Ventavis® across all global markets excluding the USA and Russia, as well as global rights to Breelib®.

The acquisition further strengthens Essential Pharma’s position in rare cardio-pulmonary disease, building on the addition of Colobreathe® in 2024, and represents another significant step in the Company’s strategy to build a global rare disease platform. The transaction reinforces Essential’s mission to enable continued access to important niche medicines and expands its growing rare disease portfolio.

Robert Watson, Managing Partner at Gyrus Capital, commented: “This acquisition represents another important step in strengthening Essential Pharma’s rare cardio-pulmonary franchise and advancing its global rare disease platform. Ventavis® is a well-established product serving a clearly defined rare patient population, fully aligned with Essential’s strategy of focusing on niche, clinically differentiated medicines. We are pleased to continue supporting the team as it executes its disciplined M&A strategy and expands its international rare disease footprint.”

Consistent with its strategy, Essential Pharma continues to focus on clinically differentiated, established products serving small patient populations where sustained access and specialised commercial expertise are critical. The addition of Ventavis® further strengthens the Company’s position in rare cardio-pulmonary disease and enhances the breadth of its specialist portfolio.

Gyrus Capital continues to support Essential Pharma’s targeted M&A strategy as it expands its international rare disease platform through the acquisition of commercial and late-stage specialty assets.

Essential Pharma is a global pharmaceutical company with a mission to develop and deliver medicines for small, underserved or rare disease populations globally. The group has a proven track record of acquiring, investing in and commercialising specialty medicines. The growing product portfolio reaches patients in approximately 70 countries across a number of therapy areas with a particular focus on rare disease, CNS, ophthalmology and gastroenterology. Essential Pharma’s investments into rare diseases include the fields of rare cardio-pulmonary and rare paediatric oncology, where its first development-stage asset is an anti-GD2 antibody for the treatment of high-risk neuroblastoma.

For more information, please visit essentialpharmagroup.com/